Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Famciclovir

FDA-approved product (tablet, oral), marketed as Famciclovir, Famvir.

Registered studies
25
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Famciclovir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Eye infection
  • Genital herpes
  • Herpes Labialis
  • Herpes Zoster
  • Immunodeficiency disease
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Nucleosides and nucleotides excl. reverse transcriptase inhibitors; Antivirals
FDA pharmacologic class
Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AB09; WHO ATC S01AD07

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA39.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli48.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae17.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis36.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

25registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Famciclovir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Famciclovir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Patient-initiated Episodic Treatment of Recurrent Genital Herpes in Black Patients

    NCT00477334 · start 2007-06

    Registered record
    Registry ID
    NCT00477334
    Conditions
    Genital Herpes
    Interventions
    Famciclovir; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-06
    Completion
    2009-03
    Enrolment
    463

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGenital Herpes
    InterventionFamciclovir; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes

    NCT00306787 · start 2006-03

    Registered record
    Registry ID
    NCT00306787
    Conditions
    Genital Herpes
    Interventions
    Famciclovir; Valacyclovir; Placebo matching famciclovir; Placebo matching valacyclovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-03
    Completion
    2008-02
    Enrolment
    1,179

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGenital Herpes
    InterventionFamciclovir; Valacyclovir; Placebo matching famciclovir; Placebo matching valacyclovir
    PhasePhase 3
    Registry statusCompleted

  • Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection

    NCT00098046 · start 2005-07

    Registered record
    Registry ID
    NCT00098046
    Conditions
    Chickenpox; Herpes Zoster
    Interventions
    famciclovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-07
    Completion
    2007-07
    Enrolment
    76

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChickenpox; Herpes Zoster
    Interventionfamciclovir
    PhasePhase 3
    Registry statusCompleted

  • Famciclovir Pediatric Formulation in Children 1 to 12 Years of Age With Herpes Simplex Infection

    NCT00098059 · start 2005-02

    Registered record
    Registry ID
    NCT00098059
    Conditions
    Herpes Simplex
    Interventions
    Famciclovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-02
    Completion
    2007-12
    Enrolment
    74

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHerpes Simplex
    InterventionFamciclovir
    PhasePhase 3
    Registry statusCompleted

  • Famciclovir 500 mg Tablets Under Fasting Conditions

    NCT00834431 · start 2004-08

    Registered record
    Registry ID
    NCT00834431
    Conditions
    Healthy
    Interventions
    Famciclovir 500 mg Tablets; Famvir® 500 mg Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2004-08
    Completion
    2004-09
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionFamciclovir 500 mg Tablets; Famvir® 500 mg Tablets
    PhasePhase 1
    Registry statusCompleted

  • Famciclovir 500 mg Tablets Under Non-Fasting Conditions

    NCT00834444 · start 2004-08

    Registered record
    Registry ID
    NCT00834444
    Conditions
    Healthy
    Interventions
    Famciclovir 500 mg Tablets; Famvir® 500 mg Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2004-08
    Completion
    2004-09
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionFamciclovir 500 mg Tablets; Famvir® 500 mg Tablets
    PhasePhase 1
    Registry statusCompleted

  • A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding

    NCT00129818 · start 2004-07

    Registered record
    Registry ID
    NCT00129818
    Conditions
    Genital Herpes
    Interventions
    Famciclovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-07
    Completion
    2005-10
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGenital Herpes
    InterventionFamciclovir
    PhasePhase 4
    Registry statusCompleted

  • A Study to Evaluate the Safety and Efficacy of Single Day or Single Dose Famciclovir for the Treatment of Recurrent Herpes Labialis

    NCT00248144 · start 2003-10

    Registered record
    Registry ID
    NCT00248144
    Conditions
    Recurrent Herpes Labialis
    Interventions
    Famciclovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-10
    Completion
    2007-07
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Herpes Labialis
    InterventionFamciclovir
    PhasePhase 4
    Registry statusCompleted

  • RELIEF: Randomized Episodic Versus Long-Term Suppression Experience With Famciclovir

    NCT00219310 · start 2003-06

    Registered record
    Registry ID
    NCT00219310
    Conditions
    Recurrent Genital Herpes (RGH)
    Interventions
    Famciclovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-06
    Completion
    2005-06
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Genital Herpes (RGH)
    InterventionFamciclovir
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes

    NCT00171990 · start 2003-01

    Registered record
    Registry ID
    NCT00171990
    Conditions
    Recurrent Genital Herpes
    Interventions
    Famciclovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-01
    Completion
    2006-02
    Enrolment
    1,461

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Genital Herpes
    InterventionFamciclovir
    PhasePhase 3
    Registry statusCompleted